Fluoxetine
- Generic Name
- Fluoxetine
- Brand Names
- Prozac, Sarafem, Symbyax
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18F3NO
- CAS Number
- 54910-89-3
- Unique Ingredient Identifier
- 01K63SUP8D
- Background
Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.
- Indication
Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present. Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar I Disorder, and treatment resistant depression. Fluoxetine is additionally indicated for the treatment of female patients with premenstrual dysphoric disorder (PMDD).
- Associated Conditions
- Alcohol Dependency, Anorexia Nervosa (AN), Bulimia Nervosa, Cataplexy, Depression, Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Myoclonus, Obesity, Obsessive Compulsive Disorder (OCD), Panic Disorder With Agoraphobia, Panic disorder without agoraphobia, Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD)
- Associated Therapies
- Maintenance therapy
Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation
- Conditions
- Interventions
- First Posted Date
- 2012-10-25
- Last Posted Date
- 2018-02-26
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 34
- Registration Number
- NCT01714310
- Locations
- 🇺🇸
UCLA Semel Institute, Los Angeles, California, United States
A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
- Conditions
- Interventions
- First Posted Date
- 2012-09-19
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 176
- Registration Number
- NCT01687478
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Xinxiang, China
Fluoxetine for Motor, Aphasia, and Neglect Recovery After Ischemic Stroke
- First Posted Date
- 2012-08-29
- Last Posted Date
- 2015-06-16
- Lead Sponsor
- Spaulding Rehabilitation Hospital
- Registration Number
- NCT01674868
- Locations
- 🇺🇸
Spaulding Rehabilitation Hospital, Boston, Massachusetts, United States
Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)
- Conditions
- Interventions
- First Posted Date
- 2012-08-24
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 64
- Registration Number
- NCT01672255
- Locations
- 🇺🇸
University of Maryland, Baltimore, Baltimore, Maryland, United States
Homeopathic Treatment for Depression in Peri- and Postmenopausal Women
- Conditions
- Interventions
- First Posted Date
- 2012-07-09
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Hospital Juarez de Mexico
- Target Recruit Count
- 133
- Registration Number
- NCT01635218
- Locations
- 🇲🇽
Hospital Juárez de México, Mexico City, Mexico
Fluoxetine Prevention Trial
- First Posted Date
- 2012-06-08
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- University of California, Los Angeles
- Registration Number
- NCT01615055
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸City of Hope, Duarte, California, United States
Repeated Partial Sleep Deprivation to Augment SSRI Response in Depression
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 68
- Registration Number
- NCT01545843
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
A Positron Emission Topographic (PET) Study on Depression Patient With Electroacupuncture
- Conditions
- Interventions
- First Posted Date
- 2011-11-28
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 36
- Registration Number
- NCT01479920
- Locations
- 🇨🇳
School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China
🇨🇳Department of Psychiatry, Queen Mary Hospital, Hong Kong, China
🇨🇳Department of Psychiatry, Kowloon Hospital, Kowloon, China
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
- Conditions
- Interventions
- First Posted Date
- 2011-09-20
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT01436643
- Locations
- 🇩🇪
Novartis Investigative Site, Zwickau, Germany
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
- Conditions
- Interventions
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 340
- Registration Number
- NCT01372150
- Locations
- 🇺🇸
Winter Park Memorial Hospital, Winter Park, Florida, United States
🇺🇸Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇲🇽CIT - Neuropsique, S.C., Monterrey, Nuevo LEON, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.